The license fee payment receivable per drug under the collaboration agreement.

No definition available.

Name:	akca_LicenseFeePaidPerDrug
Namespace Prefix:	akca_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The maximum amount of payments receivable for commercialization milestones under the collaboration agreement.

+ References

No definition available.

+ Details

Name:	akca_MaximumAmountOfPaymentsReceivableForCommercializationMilestones
Namespace Prefix:	akca_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The maximum amount of payments receivable for development milestones under the collaboration agreement.

+ References

No definition available.

+ Details

Name:	akca_MaximumAmountOfPaymentsReceivableForDevelopmentMilestones
Namespace Prefix:	akca_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The maximum amount of payments receivable for milestones under the collaboration agreement.

+ References

No definition available.

+ Details

Name:	akca_MaximumAmountOfPaymentsReceivableForMilestones
Namespace Prefix:	akca_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The maximum amount of payments receivable for regulatory milestones under the collaboration agreement.

+ References

No definition available.

+ Details

Name:	akca_MaximumAmountOfPaymentsReceivableForRegulatoryMilestones
Namespace Prefix:	akca_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The next potential milestone payment to be earned under the collaboration agreement.

+ References

No definition available.

+ Details

Name:	akca_NextPotentialMilestonePayment
Namespace Prefix:	akca_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The number of drugs with an exclusive option that could be exercised to develop and commercialize the drug and a license fee is paid under the collaboration agreement. The collaboration partner will assume all further global development, regulatory and commercialization activities for the licensed drug.

+ References

No definition available.

+ Details

Name:	akca_NumberOfDrugsWithExclusiveOptionThatCouldBeExercised
Namespace Prefix:	akca_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

The percentage of license fees, milestone payments and royalties paid as a sublicense fee to Ionis Pharmaceuticals, Inc. under the development, commercialization and license agreement and services agreement .

+ References

No definition available.

+ Details

Name:	akca_PercentageOfLicenseFeesMilestonePaymentsAndRoyaltiesPaidAsSublicenseFee
Namespace Prefix:	akca_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of the upfront payment received during the period under the collaboration agreement that was paid as a sublicense fee to Ionis Pharmaceuticals, Inc.

+ References

No definition available.

+ Details

Name:	akca_PortionOfUpfrontPaymentPaidAsSublicenseFee
Namespace Prefix:	akca_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The amount of the upfront payment received during the period under the collaboration agreement that was retained by the entity.

+ References

No definition available.

+ Details

Name:	akca_PortionOfUpfrontPaymentRetained
Namespace Prefix:	akca_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Royalty percentage received on the sales of a drug by a collaboration partner under the collaboration agreement.

+ References

No definition available.

+ Details

Name:	akca_RoyaltyPercentageReceivedOnSalesOfDrug
Namespace Prefix:	akca_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- References

No definition available.

+ Details

Name:	akca_StrategicCollaborationAgreementAbstract
Namespace Prefix:	akca_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of upfront payments received during the period under the collaboration agreement.

+ References

No definition available.

+ Details

Name:	akca_UpfrontPaymentReceived
Namespace Prefix:	akca_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-URI http://asc.fasb.org/extlink&oid=84177426&loc=d3e6351-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=77997519&loc=d3e13531-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=84177426&loc=d3e6404-108592

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77997519&loc=d3e13537-108611

+ Details

Name:	us-gaap_ConcentrationRiskPercentage1
Namespace Prefix:	us-gaap_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.4(a).Q1)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

+ Details

Name:	us-gaap_DeferredRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The cash inflow from the additional capital contribution to the entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3255-108585

+ Details

Name:	us-gaap_ProceedsFromIssuanceOfCommonStock
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

+ Details

Name:	us-gaap_Revenues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=akca_StrategicCollaborationAgreementEnteredIntoInJanuary2017WithNovartisMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=akca_AKCEAAPOALMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=akca_AKCEAAPOCIIILMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Strategic Collaboration with Novartis (Details) $ in Thousands	1 Months Ended	3 Months Ended			6 Months Ended
	Jul. 31, 2017 USD ($)	Jun. 30, 2017 USD ($)	Mar. 31, 2017 USD ($) Drug	Jun. 30, 2016 USD ($)	Jun. 30, 2017 USD ($)	Jun. 30, 2016 USD ($)
Strategic Collaboration with Novartis [Abstract]
Revenue earned		$ 14,128		$ 0	$ 23,725	$ 0
Novartis [Member]
Strategic Collaboration with Novartis [Abstract]
Number of drugs with exclusive option that could be exercised \| Drug			1
Upfront payment received			$ 75,000
Portion of upfront payment retained			60,000
Portion of upfront payment paid as sublicense fee to Ionis			$ 15,000
License fee receivable per drug		150,000			150,000
Next prospective milestone		25,000			$ 25,000
Percentage of license fees, milestone payments and royalties paid as sublicense fee to Ionis					50.00%
Revenue earned		$ 14,100			$ 23,700
Concentration percentage		100.00%			100.00%
Deferred revenue		$ 84,700			$ 84,700
Novartis [Member] \| Subsequent Event [Member]
Strategic Collaboration with Novartis [Abstract]
Proceeds from sale of common stock	$ 50,000
Novartis [Member] \| AKCEA-APO(a)-L [Member]
Strategic Collaboration with Novartis [Abstract]
Maximum amount of payments receivable for milestones		600,000			600,000
Maximum amount of payments receivable for development milestones		25,000			25,000
Maximum amount of payments receivable for regulatory milestones		290,000			290,000
Maximum amount of payments receivable for commercialization milestones		285,000			$ 285,000
Royalty percentage received on sales of drug					20.00%
Novartis [Member] \| AKCEA-APOCIII-L [Member]
Strategic Collaboration with Novartis [Abstract]
Maximum amount of payments receivable for milestones		530,000			$ 530,000
Maximum amount of payments receivable for development milestones		25,000			25,000
Maximum amount of payments receivable for regulatory milestones		240,000			240,000
Maximum amount of payments receivable for commercialization milestones		$ 265,000			$ 265,000
Royalty percentage received on sales of drug					20.00%